伴随式诊断(CDx):市场预测(2022年～2027年)

全球伴随式诊断(CDx)的市场规模，2020年为56亿3,700万美金，预计以17.68％的年复合成长率发展，至2027年达到176亿1,800万美元。

预测促进市场成长的主要理由，是慢性疾病的盛行率上升，伴随式诊断(CDx)引进市场。此外，生活水准的提高和技术的利用可能性伴随的医疗费增加，及精密医疗的需求，带给随式诊断(CDx)设备显着的商机。

本报告提供全球伴随式诊断(CDx)市场调查，市场规模和预测，市场促进因素及课题，市场趋势，各安装类型、各车辆类型、各地区的市场分析，竞争情形，主要企业的简介等系统性资讯。

目录

第1章 简介

• 市场定义
• 市场区隔

第2章 调查手法

• 调查资料
• 前提条件

第3章 摘要整理

• 调查的重点

第4章 市场动态

• 推动市场要素
• 阻碍市场要素
• 波特的五力分析
  • 供给企业谈判力
  • 买方议价能力
  • 新加入业者的威胁
  • 替代品的威胁
  • 竞争企业间的敌对关係
• 产业的价值链分析

第5章 伴随式诊断(CDX)市场:各技术

• 简介
• 聚合酵素链锁反应(PCR)
• 免疫组织化学(IHC)
• 原位杂交(ISH)
• 次世代定序(NGS)

第6章 伴随式诊断(CDX)市场:各适应症

• 简介
• 肺癌症
• 乳癌
• 大肠癌症
• 其他

第7章 伴随式诊断(CDX)市场:各地区

• 简介
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 南美
  • 巴西
  • 阿根廷
  • 其他
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 其他
• 中东、非洲
  • 沙乌地阿拉伯
  • 以色列
  • 其他
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他

第8章 竞争环境与分析

• 主要企业策略分析
• 新兴企业和市场收益性
• 合併，收购，协定，及合作
• 供应商竞争力矩阵

第9章 企业简介

• Abbott
• Aglient Technolgies Inc.
• Arup Laboratories
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Invivoscribe, Inc
• Myriad Genetics, Inc.
• QIAGEN
• Thermo Fisher Scientific Inc.

The companion diagnostics (CDx) market is projected to witness a compound annual growth rate of 17.68% to grow to US$17.618 billion by 2027, from US$5.637 billion in 2020.

A companion diagnostic device is a medical device that enables the user to receive crucial information regarding the use of corresponding drugs or biological products. The prime reason which is forecasted to drive the market growth is the rising prevalence of chronic diseases which has increased the market adoption of companion diagnostics. Furthermore, increasing healthcare expenditure with the rise in the standard of living and availability of technology coupled with demand for precision medicine has created notable opportunities for the companion diagnostic device.

Based on geography, the companion diagnostics (CDx) market is segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The Asia Pacific region is forecasted to hold a substantial share of the market owing to a surge in medical tourism and advancement in the medical sector. The North American and European regions are projected to hold the largest share of the market with an increase in healthcare spending.

A next-generation sequencing companion diagnostic is expected to hold a notable share of the market.

Based on technology, the companion diagnostic market can be distinguished as a polymerase chain reaction, immunohistochemistry, in-situ hybridization, and next-generation sequencing. A next-generation sequencing companion diagnostic is expected to hold a significant share of the market, owing to technological effectiveness and better market prospects.

Lung and Breast Cancer indication is expected to dominate the market for a companion diagnostic.

By indication, the companion diagnostic market can be segmented into lung cancer, breast cancer, colorectal cancer, and others. Lung and breast cancer indication is expected to dominate the companion diagnostic market, owing to a higher number of cases. Lung and breast cancer are the two most prevalent types of cancers. These two are also the form of cancers with the highest number of deaths. A report published by the World Health Organization (WHO) shows that in 2020, there were 2.26 million cases of breast cancer, while 2.21 million cases of lung cancer. Breast cancer caused 685 thousand deaths in 2020, while lung cancer killed 1.80 million people. The growing prevalence of these forms of cancers is expected to create significant demand for a companion diagnostic.

Growth Factors

• Rising cases of cancer

One of the prime reasons supporting the growth in the companion diagnostics (CDx) market is the surging cancer cases. Companion diagnostic notably helps in cancer diagnostic and treatment. The device facilitates identifying a specific therapeutic solution for an individual suffering from cancer. A rise in cancer cases is expected to drive notable demand for companion diagnostic devices. Data from National Cancer Institute, NIH shows that 1.806 million new cases of cancer were diagnosed in the United States in 2020, increasing the rate of new cancer cases to 442.4% per 100,000 people. The rise in cancer cases is expected to surge the demand for diagnostic and treatment, hence supporting the market for a companion diagnostic.

• The surge in healthcare expenditure

Another key factor that supports the market for companion diagnostics (CDx) is a surge in healthcare expenditure with the rise in the standard of living and the adoption of advanced medical technology. Data from The World Bank shows that global per capita healthcare expenditure has been increasing at a remarkable rate. Per capita healthcare expenditure reached US$1,110.286 in 2018 from US$1,020.88 in 2016. Promising investment in the industry is expected to expand the market prospects further. In the US, for instance, healthcare expenditure is expected to grow at a CAGR from 2019 to 2028 and is expected to reach US$6.2 trillion by 208, from US$4.1 trillion in 2020. It is expected to invest in the healthcare industry and is projected to provide exceptional growth opportunities.

COVID Insights

The coronavirus pandemic resiliently impacted the market for a companion diagnostic. The surge in cases and the emergency situation created by the robust spread of the COVID-19 led to more fund investment towards the vaccination and hence impacted the market for a companion diagnostic. Furthermore, fear of catching the virus refrained patients from going for regular checks, which impacted the discovery of new or potential cases and affected the market prospects.

Key Development

• April 2021, Approval. The FDA gave a green signal to the country's first-ever companion diagnostic device developed especially for endometrial cancer diagnosis, innovated by Roche. Ltd. The VENTANA MMR RxDx Panel developed by the latter successfully identifies endometrial cancer and helps in its treatment. Annually, around 90 thousand women die due to endometrial cancer. The companion diagnostic developed by Roche can identify the patient's eligibility for JEMPERLI monotherapy.

Market Segmentation:

• By Technology

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

In-situ Hybridization (ISH)

Next-Generation Sequencing (NGS)

• By Indication

Lung Cancer

Breast Cancer

Colorectal Cancer

Others

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• United Kingdom
• Italy
• Others

Middle East and Africa

• Saudi Arabia
• Israel
• Others

Asia Pacific

• China
• India
• Japan
• South Korea
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Definition
• 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. COMPANION DIAGNOSTICS (CDX) MARKET, BY TECHNOLOGY

• 5.1. Introduction
• 5.2. Polymerase Chain Reaction (PCR)
• 5.3. Immunohistochemistry (IHC)
• 5.4. In-situ Hybridization (ISH)
• 5.5. Next-Generation Sequencing (NGS)

6. COMPANION DIAGNOSTICS (CDX) MARKET, BY INDICATION

• 6.1. Introduction
• 6.2. Lung Cancer
• 6.3. Breast Cancer
• 6.4. Colorectal Cancer
• 6.5. Others 

7. COMPANION DIAGNOSTICS (CDX) MARKET, BY GEOGRAPHY 

• 7.1. Introduction 
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others 
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Italy
  • 7.4.5. Others 
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. Israel
  • 7.5.3. Others
• 7.6. Asia Pacific 
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Others 

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Emerging Players and Market Lucrativeness
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

• 9.1. Abbott
• 9.2. Aglient Technolgies Inc.
• 9.3. Arup Laboratories
• 9.4. F. Hoffmann-La Roche Ltd
• 9.5. Illumina, Inc.
• 9.6. Invivoscribe, Inc
• 9.7. Myriad Genetics, Inc.
• 9.8. QIAGEN
• 9.9. Thermo Fisher Scientific Inc.